Quadruple therapy should be 'new therapeutic standard' for heart failure, say researchers

Treatment with a four-drug regimen incorporating newer classes of treatment can meaningfully extend the lives of patients with heart failure with reduced ejection fraction (HFrEF), a new analysis published in The Lancet suggests.

by Chloe Harman
Newer drug therapies are known to individually improve outcomes in patients with chronic HFrEF, but their aggregate benefits have not previously been explored. | SCIENCE PHOTO LIBRARY
Newer drug therapies are known to individually improve outcomes in patients with chronic HFrEF, but their aggregate benefits have not previously been explored. | SCIENCE PHOTO LIBRARY

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package